Introducton to Mounjaro (Tirzepatide) and Q&A with Prof. S.H. Yeo?

What is Mounjaro (Tirzepatide)?

Mounjaro, also known as Tirzepatide, is a cutting-edge medication initially developed for the treatment of Type 2 diabetes. It has now been recognized for its significant potential in managing obesity. Mounjaro works by enhancing insulin sensitivity, promoting insulin secretion, reducing glucagon secretion, and slowing down the emptying of the stomach. These combined effects contribute to effective weight management.

How Does Mounjaro Work?

Mounjaro functions through several mechanisms that make it effective for weight management and potentially beneficial for individuals with brain injuries:

1. Insulin Sensitivity: Mounjaro improves the body's response to insulin, helping to regulate blood sugar levels more efficiently.
2. Insulin Secretion: It increases the secretion of insulin, which helps to lower blood sugar levels.
3. Glucagon Reduction: By reducing the secretion of glucagon, a hormone that raises blood sugar levels, Mounjaro helps to maintain a more stable blood glucose level.
4. Gastric Emptying: Mounjaro slows down the rate at which the stomach empties, which helps to control appetite and reduce food intake.

Benefits for Individuals with Brain Injuries

For individuals with brain injuries, maintaining a healthy weight is crucial for overall recovery and rehabilitation. Obesity can complicate the healing process and lead to additional health issues. Mounjaro's ability to aid in weight management can provide several benefits:

• Improved Mobility: Weight loss can enhance mobility and physical function, which is often a challenge for individuals recovering from brain injuries.
• Better Blood Sugar Control: Stabilizing blood sugar levels can improve cognitive function and overall brain health.
• Reduced Inflammation: Lowering body weight can reduce systemic inflammation, which is beneficial for brain health and recovery.

Important Information for Clients

Dosage and Administration:

• The initial dosage is 2.5 mg injected subcutaneously once a week for the first four weeks.
• The dose can be increased by 2.5 mg weekly, with further adjustments up to 15 mg weekly based on individual response.

Side Effects

• Common side effects include decreased appetite, gastrointestinal discomfort (such as constipation, diarrhoea, nausea, and vomiting), and potential hypersensitivity reactions.
• Most gastrointestinal side effects typically subside after the first four weeks of treatment.
• Special Considerations:
• Pregnancy and Breastfeeding: Mounjaro is not recommended during pregnancy and should be used with caution during breastfeeding.
• Missed Doses: If a dose is missed by more than four days, skip the missed dose and proceed with the next scheduled dose.

Storage

• Store Mounjaro in the refrigerator (2–8℃) and protect it from light. It can also be kept at room temperature (below 30℃) for up to 21 days.

References and Further Reading

1. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity". New England Journal of Medicine.
2. Cai, W., Zhang, R., Yao, Y., et al. "Tirzepatide as a Novel Effective and Safe Strategy for Treating Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". 
3. BNF on Tirzepatide

I